Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.
Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Lupus. 2021 Apr;30(5):836-839. doi: 10.1177/0961203321989791. Epub 2021 Jan 28.
We report a case of COVID-19 in a pediatric patient with systemic lupus erythematosus (SLE), who presented with respiratory distress marked by increased work of breathing and low oxygen saturation. Lab tests confirmed COVID-19, and showed lymphocytopenia and elevated markers of inflammation and coagulopathy. Chest X-ray showed bilateral mid-lung opacities, and the patient required intubation early in his disease course. Imaging and clinical findings were consistent with acute respiratory distress syndrome (ARDS) with inflammation. The patient was treated with different combinations of antivirals (hydroxychloroquine and remdesivir), cytokine inhibitors (anakinra and tocilizumab), glucocorticoids (hydrocortisone and methylprednisolone), and an anticoagulant (enoxaparin). Inflammatory markers decreased before clinical improvement in lung aeration. This case highlights the potential for pediatric patients with SLE to present with COVID-19 similar to the clinical presentation described in adults.
我们报告了一例 COVID-19 合并系统性红斑狼疮(SLE)的儿科患者,该患者以呼吸急促为特征,表现为呼吸功增加和低氧饱和度。实验室检查证实了 COVID-19,同时伴有淋巴细胞减少和炎症及凝血功能障碍标志物升高。胸部 X 线显示双肺中肺野渗出影,患者在疾病早期需要插管。影像学和临床发现与炎症性急性呼吸窘迫综合征(ARDS)相符。该患者接受了不同组合的抗病毒药物(羟氯喹和瑞德西韦)、细胞因子抑制剂(阿那白滞素和托珠单抗)、糖皮质激素(氢化可的松和甲泼尼龙)和抗凝药物(依诺肝素)治疗。在肺部通气改善之前,炎症标志物先于临床改善而降低。该病例提示 SLE 儿科患者可能会出现类似于成人描述的 COVID-19 临床表现。